NIH Funds NCI Research for Neuroblastoma T-Cell Therapy IND Application
What happened
The National Cancer Institute received a Phase II grant of $2,058,885 from the National Institutes of Health. This funding supports the advancement of ET501, an investigational T-cell therapy designed for children with high-risk neuroblastoma, toward an Investigational New Drug application to the U.S. Food and Drug Administration.
From prnewswire.com
Why it matters
The award supports the clinical-stage research of a gene and cell therapy aimed at treating a pediatric cancer. The funding helps the therapy progress through the necessary steps required for regulatory review by the U.S. Food and Drug Administration.
From prnewswire.com
Who's involved
- National Institutes of HealthGovernment organization that awarded the Phase II research grant.
- National Cancer InstituteSubsidiary of the National Institutes of Health that conducted the research.
- FDARegulatory agency to which the research is being prepared for submission.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- National Cancer InstituteSpeculative
The National Cancer Institute could see increased research costs covered by the grant funding.
Keep exploring
The entities involved
- FDA
-
National Institutes of Health
government organization in Shah Alam, Malaysia
-
National Cancer Institute
public hospital in Milan dedicated to cancer care
Related events
- NIH funding supports cancer centers and job creation in Oklahoma.
- FDA provided guidance for HCW Biologics' IND application.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- The National Institutes of Health funded research at Quillen College of Medicine.